Arbutus Biopharma (ABUS) Other Non-Current Assets (2010 - 2026)
Arbutus Biopharma (ABUS) posted Other Non-Current Assets of $131000.0 for Q1 2026, up 0.77% sequentially from $130000.0 in Q4 2025, and up 285.29% YoY from $34000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Other Non-Current Assets for 13 years, with the latest figure at $131000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 285.29% year-over-year to $131000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131000.0 (up 285.29% YoY) and the FY2025 annual result came in at $130000.0, up 282.35% from the prior year.
- Other Non-Current Assets advanced to $131000.0 in Q1 2026 per ABUS's latest filing, from $130000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $190000.0 in Q1 2022 and troughed at $3000.0 in Q3 2023.
- A 5-year average of $98000.0 and a median of $116500.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets tumbled 98.2% in 2023, then jumped 285.29% in 2026.
- Over 5 years, Other Non-Current Assets stood at $103000.0 in 2022, then tumbled by 97.09% to $3000.0 in 2023, then surged by 1033.33% to $34000.0 in 2024, then soared by 282.35% to $130000.0 in 2025, then climbed by 0.77% to $131000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $131000.0, $130000.0, and $131000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 131,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 103,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | 180,000.00 |
| Mar 31, 2022 | 190,000.00 |
| Dec 31, 2021 | 61,000.00 |
| Dec 31, 2020 | 44,000.00 |
| Sep 30, 2020 | 109,000.00 |
| Jun 30, 2020 | 173,000.00 |
| Mar 31, 2020 | 233,000.00 |
| Dec 31, 2019 | 293,000.00 |
| Mar 31, 2015 | -155.87 Mn |